Παρασκευή 5 Μαΐου 2017

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

J Clin Oncol. 2017 May 04;:JCO2016718072

Authors: Szturz P, Seiwert TY, Vermorken JB

PMID: 28471725 [PubMed - as supplied by publisher]



from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pH1Jyw
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις